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462Objective: Current literature assessing factors associated with outcomes of patients waiting for pediatric heart
transplants has focused on survival to transplant and mortality. Our aim was to determine risk factors associated
with the outcomes of delisting, transplant, or death while waiting.
Methods: In this single-center, retrospective study of patients listed for heart transplants, competing risk
analysis was used to model survival from listing to 4 competing outcomes (transplant, death, delisting for
clinical deterioration, delisting for clinical improvement or surgical intervention).
Results: There were 308 listing episodes in 280 patients. In competing risk analysis, 11% remained listed at
6 months (transplant 62%, dead 13%, delisted worse 6%, delisted improved 8%). Extracorporeal membrane
oxygenation and ventricular assist devices were associated both with higher probability of transplant
(hazard ratio [HR], 2.8; P<.001) and delisting for clinical deterioration (HR, 2.7; P ¼ .06). Younger age at
listing and complex congenital heart disease were shared risk factors for mortality (HR, 1.07; P ¼ .05; HR,
2.9; P ¼ .003) and delisting because of clinical deterioration (HR, 1.17; P ¼ .01; HR, 2.8; P ¼ .02). Younger
age at listing and fetal listing were associated with delisting for clinical improvement or surgical intervention
(HR, 1.13; P ¼ .01; HR, 2.9; P ¼ .02).
Conclusions: Overall survival to transplant depends on risk factors including age at listing, cardiac diagnosis,
and mechanical circulatory support. Knowledge of risk factors for death and delisting for clinical
deterioration or improvement can assist patient selection and timing of transplant listing. (J Thorac Cardiovasc
Surg 2014;147:462-8)Pediatric patients waiting for heart transplants have the
highest waiting list mortality relative to all other solid or-
gan transplant groups.1-4 Many factors affect how long a
patient is expected to wait for a transplant such as
weight, blood group, age, underlying diagnosis, and
HLA sensitization.2,5,6 Organ allocation algorithms aim
to stratify patients by risk factors for death to optimize
organ allocation and reduce waiting list mortality.
Recent studies, however, highlight that the current
systems may be imperfect and point out that there is a
need for ongoing review of the existing algorithms with
a clear view to achieving optimal patient outcomes
during the wait for transplant.7,8 Currently, the Canadian
organ allocation system (COAS) for pediatric heart
transplantation stratifies patients according to level of
medical urgency, with further definitions for each levele Labatt Family Heart Centre, Hospital for Sick Children, Toronto, Ontario,
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The Journal of Thoracic and Cardiovascular Surgof ‘‘critical illness’’ comparable to the one in use by the
United Network for Organ Sharing (UNOS; Table 1).
Thus a patient that who is receiving mechanical ventila-
tion and mechanical circulatory support (MCS) will have
a higher waiting list status than that of a patient receiving
high-dose inotropes alone, regardless of time spent on the
waiting list.
Almond and colleagues8 reported waiting list mortality in
the United States according to data from the Scientific
Registry of Transplant Recipients (SRTR). Overall waiting
list mortality was 17%, but more importantly there was
considerable heterogeneity within the highest medical
urgency category, status 1A, which comprised 60% of the
listings. Status 1A patients had a waiting list mortality
that ranged from 5% to 39%, depending on their level
of hemodynamic support. This study concluded that,
despite improvements in the organ allocation system since
1999, pediatric waiting list mortality continues to remain
unacceptably high, and the current organ allocation system
in the United States remains suboptimal for characterizing
medical urgency.8
Previous studies assessing factors associated with
waiting list outcomes have mainly focused on survival to
transplant and mortality.2,4,6,9-13 Of equal importance,
however, are factors associated with removal from
the waiting list, or ‘‘delisting,’’ whether for clinicalery c January 2014
Abbreviations and Acronyms
ABO-I ¼ ABO incompatible
CAV ¼ cardiac allograft vasculopathy
CHD ¼ congenital heart disease
COAS ¼ Canadian organ allocation system
ECMO ¼ extracorporeal membrane oxygenation
HLHS ¼ hypoplastic left heart syndrome
MCS ¼ mechanical circulatory support
SRTR ¼ Scientific Registry of Transplant
Recipients
UNOS ¼ United Network for Organ Sharing
Jeewa et al Cardiothoracic Transplantationdeterioration or for clinical improvement, surgical
intervention, or both. These expansions on the
conventional risk factor analyses for delisting may help
with decision making related to heart transplant eligibility
and timing of listing, and they may contribute to optimal
risk stratification within organ allocation algorithms.
The purpose of this study was to assess our institution’s
waiting list mortality within the current COAS and the
associated risk factors for delisting because of clinical
deterioration or delisting because of clinical improvement
or surgical intervention.T
XMATERIALS AND METHODS
This was a retrospective study of all patients listed for heart transplants
for congenital or acquired heart disease at The Hospital for Sick Children,
Toronto, Ontario, Canada, between 1990 and 2008. Research ethics board
approval was obtained,. Detailed medical history was reviewed, including
cardiac diagnosis, medical condition leading to the transplant, blood group,
requirement for MCS, fetal listing, and waiting list outcomes. Status at the
time of listing was according to the COAS. Table 1 outlines the comparison
between the COAS and that of UNOS.
Data are described as means with SD, medians with minimum and
maximum values, and frequencies as appropriate. A competing risks
analysis was performed to characterize outcomes after pediatric patients
were listed for heart transplants. The competing risk analysis estimates,
at each time point after listing, the likelihood of each competing event
occurring against all others, according to a parametric survival model for
each event. To create the competing risks, parametric survival models
were created for each of the following competing outcomes: (1) heart
transplant, (2) death on the transplant list, (3) delisting because of clinical
deterioration or loss of transplant candidacy, and (4) delisting because of
clinical improvement or other surgical intervention. Factors associated
with each of these outcomes were sought from demographic and clinical
characteristics in univariate models and excluded patient status at listing,
which was considered a surrogate marker of likelihood of outcomes.
Factors with associations at the level of P < .10 were included in
multivariable models with backward selection to obtain a final model.
All statistical analyses were performed with SAS Statistical Software
version 9.2 (SAS Institute Inc, Cary NC).RESULTS
Patient Population
There were 308 listing episodes for heart transplants
among 280 pediatric patients, 45% of whom were male,The Journal of Thoracic and Cawith a median age at listing of 1.6 years (ranging from fetal
listing to 17.9 years). A total of 121 patients (39%) were
eligible and listed for ABO-incompatible (ABO-I) heart
transplants. There was a slight predominance of patients
with congenital heart disease (CHD) listed for their first
heart transplant (58%), and approximately a third of those
had undergone a previous surgical procedure (37%). There
was the expected predominance of patients belonging to
blood group O (49%). Detailed characteristics of the study
population can be found in Table 2.
Overall Outcomes After Listing for Transplant
For the entire cohort, 70% patient listings (n ¼ 216)
eventually resulted in transplants, 13% of patients
(n ¼ 40) died while on the waiting list, 7% (n ¼ 21) were
delisted because of clinical worsening, 9% (n ¼ 29) were
delisted because of clinical improvement or other surgical
intervention, and 1% (n ¼ 2) had yet to reach an outcome
at the 2-year mark (Figure 1). Median time from listing to
reaching an outcome was 29 days (1-930 days). Despite a
low overall waiting list mortality of 13%, the range
according to the underlying diagnosis or level of support
was quite variable. Factors associated with the highest
percentagewaiting list mortality while waiting in our cohort
were being relisted for primary graft failure (30%),
Canadian transplant status 4 (23%), extracorporeal
membrane oxygenation (ECMO) support (21%), age
younger than 1 month (18%), and complex CHD other
than hypoplastic left heart syndrome (HLHS; 16%).
Patients who were listed status 4, the highest status
according to the COAS, had the shortest time to an outcome
(death, transplant, or delisting) relative to status 1 patients
(median 10 days vs 64 days; P < .001) but the lowest
transplant rate (52% vs 83%, P< .001). Status 4 at the
time of listing was also associated with younger age at
listing (P ¼ .04), listing eligible for an ABO-I transplant
(P ¼ .01), use of ventricular assist device (VAD) or
ECMO (P < .001), diagnoses other than restrictive
cardiomyopathy (P ¼ .004) or cardiac allograft
vasculopathy (CAV) (P ¼ .04), and primary graft failure
(P<.001).
Risk Factor Analysis
Multivariate analysis indicated that patients with blood
group A possessed an expected competitive edge, with a
significantly higher likelihood of surviving to transplant
(hazard ratio [HR] 2.1 vs all other blood groups;
P < .001), whereas those with blood group O were
significantly less likely to survive to transplant (HR, 0.5;
P<.001). Differences between blood groups were negated
in young patients listed for ABO-I transplant, resulting in a
higher likelihood of successfully surviving to transplant
(HR, 1.4; P ¼ .03). Younger age at listing (<1 month)
was associated with increased likelihood of death on therdiovascular Surgery c Volume 147, Number 1 463
TABLE 1. United Network for Organ Sharing and Canadian organ allocation system conversion
Canadian Criteria UNOS Criteria
4 VAD or Berlin Heart (infants); mechanically ventilated on high-
dose single or multiple inotropes with or without mechanical
circulatory support; patients should be recertified every 7 d as
status 4 by a qualified physician if still medically appropriate
1A Requires assistance with a ventilator; requires assistance with
MCS or balloon pump; candidate who does not meet other
status 1A criteria may be listed as status 1A if the candidate
has a life expectancy without a heart transplant of<14 d, such
as for refractory arrhythmia; qualification for status 1A under
this criterion is valid for 14 d and may be recertified by an
attending physician for 1 additional 14-d period; any further
extension of the status 1A listing requires a conference with
the RRB
3.5 Infant<6 mo; CHD and PGE dependent; high-dose or multiple
inotropes in hospital and not candidate for VAD therapy; high
PRA (>80% or elevated with 3 previous positive
crossmatches); acute ventricular arrhythmias
Infant<6 mo with CHD or AHD exhibiting reactive PHTN at
>50% of systemic level; such a candidate may be treated with
PGE infusion; requires infusion of high-dose or multiple
inotropes
3 Inotropic support not meeting previously stated criteria; VAD
not meeting status 4 criteria; heart-lung transplant candidates
Candidate who does not meet previously stated criteria may be
listed as status 1A if candidate has a life expectancy<14 d
Infant<6 mo with CHD; cyanotic CHD with resting saturation
<65%; CHD that is arterial shunt dependent; inpatient CPAP
or BIPAP support
1B Requires infusion of low-dose single inotrope; infant<6 mo and
does not meet status 1A criteria
2 Growth failure (<5th percentile for weight or height or loss of
1.5 SD of expected growth)
Growth failure (<5th percentile for weight or height, or loss of
1.5 SD of expected growth (height or weight); candidate who
does not meet criteria for status 1B may be nevertheless
assigned to such status on application by transplant
physician(s) and justification to the applicable RRB
Home CPAP or BIPAP; hospital management for CHF not
meeting previously stated criteria; CHD with resting
saturation 65%-75% or prolonged desaturation to<60%
with activity; Fontan palliation with PLE; MOT recipient
2 Candidate that does not meet criteria for status 1A or 1B is listed
as status 2
1 All other out-of-hospital patients; in utero listing
UNOS, United Network for Organ Sharing; VAD, ventricular assist device; MCS, mechanical circulatory support; RRB, regional review board; CHD, congenital heart disease;
PGE, prostaglandin E; PRA, panel reactive antibodies; AHD, acquired heart disease; PHTN, pulmonary hypertension; CPAP, continuous positive airway pressure; BIPAP, bilevel
positive airway pressure; CHF, congestive heart failure; PLE, protein losing enteropathy; MOT, multiorgan transplant; SD, standard deviation.
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Xwaiting list (HR, 1.07/y; P¼ .05), delisting because of clin-
ical deterioration (HR, 1.17/y; P ¼ .01), or delisting
because of clinical improvement or surgical intervention
(HR, 1.13/y; P¼ .01; HR, 2.9 for fetal listing; P¼ .02). Pa-
tients who were relisted because of primary graft failure
were more likely to die waiting (HR, 9.7; P ¼ .001), as
were patients with complex CHD (HR, 2.9; P ¼ .003),
who were also more likely to be delisted because of clinical
worsening (HR, 2.8; P¼ .02). Patients relisted for CAV had
a high likelihood of surviving to transplant (92% by 1 year)
but had the longest wait time (median 159 days; 4-858 days)
versus primary graft failure (median 7 days; 2-40 days;
P<.001). Patients without previous surgical interventions
or palliations were at higher risk of dying on the list (HR,
3.6; P ¼ .004), whereas those requiring MCS, either VAD
or ECMO, were more likely to be delisted because of clin-
ical deterioration (HR, 2.7; P ¼ .06; Table 3).
Delisting for Clinical Worsening or Loss of
Transplant Candidacy
With respect to patients that were initially listed as status
4, 15% were delisted because of clinical deterioration by464 The Journal of Thoracic and Cardiovascular Surg6 months. For patients whose status progressed from an
initial listing of status 1, 2, or 3 to a higher status while
waiting (n ¼ 39), none were delisted because of clinical
deterioration at any point during follow-up. Blood groups
O and A had similar numbers of patients who were delisted
because of clinical deterioration (6% vs 5% by 6 months).
Blood groups B (10%) and AB (15%) both had increased
numbers of patients who were delisted because of clinical
deterioration after 6 months of waiting, which was probably
affected by the relative smaller sample size and the rarity of
these blood groups in the Canadian population. The cardiac
diagnosis also differed among patients who were delisted
for clinical deterioration, with 5% in the HLHS group
and 10% in the complex CHD group.
Delisting for Clinical Improvement or Surgical
Intervention
Of the patients who were listed as Canadian status 4,
10% were eventually delisted because of clinical improve-
ment. Fifteen percent of patients with HLHS were delisted
because of clinical improvement or were offered another
surgical intervention by 6 months after listing, comparedery c January 2014
TABLE 2. Patient characteristics at time of listing (N ¼ 308)
Demographics and clinical features
Male sex 140 (45%)
Age at listing (y, median and range) 1.6 (0.0-17.9)
Fetal listing 25 (8%)
Diagnosis
HLHS 73 (24%)
Complex CHD other than HLHS 106 (34%)
Dilated cardiomyopathy 73 (24%)
Restrictive cardiomyopathy 18 (6%)
Other cardiomyopathy 11 (4%)
EFE or LV tumor 5 (1%)
Primary graft failure 10 (3%)
Graft vasculopathy 12 (4%)
Blood group
A 105 (34%)
AB 13 (4%)
B 41 (13%)
O 149 (48%)
Rh positive (N ¼ 307) 253 (82%)
Previous surgery 113 (37%)
Listed for first transplant 286 (93%)
Listed for second transplant 20 (6%)
Listed for third transplant 2 (1%)
Transplant listing
Available for ABO-incompatible transplant 121 (39%)
Status at listing (N ¼ 306)
1 71 (23%)
2 35 (11%)
3A 78 (25%)
3B 7 (2%)
4 115 (38%)
Status at outcome (N ¼ 306)
1 67 (22%)
2 24 (8%)
3A 69 (22%)
3B 9 (3%)
4 137 (45%)
Status worsened on list (N ¼ 306) 39 (13%)
ECMO or VAD 59 (19%)
Outcomes
Transplant 216 (70%)
Death 40 (13%)
Delisted because of clinical deterioration 21 (7%)
Condition improved or surgical option 29 (9%)
Median time from listing to any outcome
(d, median and range)
29 (1-930)
Time to outcome (d, median and 5th-95th percentile)
Transplanted 37.5 (2.0-413)
Death 13.5 (1-102.5)
Delisted because of clinical deterioration 10.0 (3-140)
Surgical intervention 32.0 (3-185)
Clinical improvement 20.0 (6-312)
Data represent numbers and percentages of patients unless otherwise marked.
HLHS, Hypoplastic left heart syndrome; CHD, congenital heart disease;
EFE, endocardial fibroelastosis; LV, left ventricular; ECMO, extracorporeal
membrane oxygenation; VAD, ventricular assist device.
FIGURE 1. Competing risks for outcomes after listing for heart
transplant. Patients can transition to any of the 4 outcomes after listing.
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The Journal of Thoracic and Cawith 8% with complex CHD. There were 12 children
(3.9%) who were delisted for another surgical intervention.
Of these, 6 were infants with HLHS who were fetal listings
for heart transplant, 2 were nonfetal listings with HLHS,
and 4 were nonfetal listings for complex CHD other than
HLHS. At the time of censoring, 3 of the patients for
whom surgical intervention had been chosen were dead,
7 were alive, and 2 had been lost to follow-up.DISCUSSION
Decision making regarding eligibility and timing of
listing for heart transplant remains challenging in the
pediatric patient approaching end-stage heart failure.TABLE 3. Multivariate analysis of risks factors for outcomes after
listing for heart transplant
Factor HR (95% CI) P value
Higher probability of transplant
ECMO or VAD 2.8 (1.9-4.0) <.001
Blood group A 2.1 (1.6-2.8) <.001
Listed for ABO-incompatible transplant 1.4 (1.0-1.8) .03
Primary graft failure 4.4 (2.0-9.7) <.001
Higher probability of death while waiting
Younger age at listing (per y) 1.07 (1.00-1.14) .05
Complex congenital heart disease 2.9 (1.5-5.6) .003
No previous surgery 3.6 (1.0-12.5) .004
Primary graft failure 9.7 (2.8-33.8) .001
Higher probability of being delisted (clinical deterioration)
Younger age at listing (per y) 1.17 (1.03-1.32) .01
ECMO or VAD 2.7 (0.9-7.7) .06
Complex congenital heart disease 2.8 (1.2-6.9) .02
Higher probability of being delisted (improved or surgical intervention)
Younger age at listing (per y) 1.13 (1.02-1.25) .01
Fetal listing 2.9 (1.2-7.2) .02
HR, Hazard ratio; CI, confidence interval; ECMO, extracorporeal membrane
oxygenation; VAD, ventricular assist device.
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an optimal outcome after transplant. The unpredictable
factor is the timing of donor organ availability, leading to
the need to balance a ‘‘too early’’ timing of listing versus
the risk of dying on the waiting list or clinical deterioration
that would render a patient no longer a candidate for
transplant. We strove to identify risk factors both for
waiting list mortality and for delisting within the COAS,
which varies from that of UNOS by its stratification of
patient medical acuity.
This study highlights the largest and longest reported
experience of transplant waiting list outcomes in Canada.
The institutional waiting list mortality was 13% overall,
compared with the 17% reported in the recent SRTR
data.8 Currently in the United States, most patients listed
for pediatric heart transplant are status 1A, especially
younger patients.14 This differs from the COAS, in which
patients listed at status 3, 3.5, or 4 could all potentially
qualify as status 1A in the United States. The analysis of
the SRTR data by Almond and colleagues8 looked at 3098
pediatric patients listed for heart transplant from 1999 to
2006. That study outlined a dramatic range for the waiting
list mortality in the UNOS status 1A, depending on the level
of respiratory and hemodynamic support. Organ allocation
goes to the patient with the greatest accrued time on the
waiting list, as opposed to the one with the highest risk for
death while waiting. The level of ‘‘critical illness’’ is a
heterogenic identifier and has been associated with poorer
outcomes while waiting for an organ. Almond and
colleagues8 showed in their competing outcomes analysis
for status 1A patients that not all status IA patients were
the same. Those patients on ECMO support had the worst
outcomes, relative to both those requiring ventilatory sup-
port and to those with neither form of support. This suggests
that there is a subgroup of patients that, although they meet
criteria for status 1A, can afford to wait longer than others
who have requirements for mechanical support. This is
the crux of the difference between the COAS and UNOS:
there is wider stratification ofmedical urgency in the COAS.
Risk Factors for Waiting List Mortality
Previous studies to date have reported risk factors for
death while waiting for a transplant that include age,
diagnosis, blood group, HLA sensitization, listing strategy,
and medical status, especially the need for mechanical
support.5,8,11,15,16 Multivariate predictors of waiting list
mortality in the United States included ECMO support,
mechanical ventilation, CHD, status 1A, need for dialysis,
nonwhite ethnicity, and a glomerular filtration rate less
than 50 mL/min/1.73 m2.8 Age was not found to be
statistically significant for waiting list mortality; this is
contrary to our data, which showed that younger patients
had elevated risks while waiting for an organ both of death
and of being delisted because of clinical worsening.466 The Journal of Thoracic and Cardiovascular SurgIn addition, we observed that complex CHD (other than
HLHS) and primary graft failure were risk factors for death
while waiting. With respect to blood group as a risk factor
for waiting list mortality, Morrow and colleagues6 reported
that patients in blood group O had the longest wait times and
have high waiting list mortality relative to other blood
groups. Our study also observed this disadvantage for blood
group O recipients. Consideration of donor availability
could not be factored into predictive models and
probably varies between Canada and the United States.
Thus, Canadian centers should consider younger patients,
patients with complex CHD, and patients with blood group
O for earlier listing for heart transplants. These risk factors
suggest areas of further improvement in optimizing the
COAS. A discussion about relisting for primary graft failure
is beyond the scope of this article, but it remains a
significant risk factor for death while wait-listed, and
relisting remains controversial.
Delisting for Clinical Deterioration or Loss of
Transplant Candidacy
The infant population in particular is at risk either for
delisting because of clinical deterioration or loss of trans-
plant candidacy or for death.12,16,17 The 2009 SRTR data
show an annual death rate of 1361 per 1000 patient-years
at risk for infants younger than 1 year in 2008, compared
with 170 for all age groups combined (adult and pediat-
ric).14 With the implementation of an ABO-I transplant pro-
tocol in the COAS, a decrease in the waiting list mortality
for infants younger than 6 months, from 58% to 7%, was
observed.18 Despite this, patients with complex CHD had
the highest waiting list mortality (16%) and the highest
incidence of being delisted because of clinical deterioration
(10%), with a lower incidence of delisting because of clin-
ical improvement or surgical intervention than those with
HLHS (8% vs 16%). This suggests a subgroup of patients
who have reached their limit for surgical repair or palliation
and also risk becoming ineligible for a transplant, represent-
ing a group that should be considered for earlier listing.
Delisting for Clinical Improvement or Surgical
Intervention
Our experience was comparable to the SRTR data with
respect to the patients who were delisted because of a
clinical improvement (9% vs 8%). Our institution has
historically offered fetal listing to prospective parents for
fetuses with a diagnosis of complex CHD or HLHS.19
Some of those patients listed for transplant as fetuses
were delisted at birth to undergo a surgical intervention,
which explains this observation.19
Pretransplant Diagnosis
Patients with cardiomyopathies have better waiting list
outcomes than do patients with CHD. 4,8,20 In our study,ery c January 2014
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with restrictive cardiomyopathy had received transplants
by 6 months, compared with 59% of those with HLHS
and 55% of those with complex CHD in the same period.
Previously reported data from our institution (1989-1998),
found a 16% waiting list mortality for patients with
cardiomyopathy, compared with waiting list mortalities of
10% for dilated cardiomyopathy and 11% for restrictive
cardiomyopathy in the current study.13 This apparent
decrease in the waiting list mortality for patients with
cardiomyopathy possibly reflects an era effect with
subsequent MCS innovations in the management of pediat-
ric heart failure. The most common cause for long-term
allograft failure is CAV, which is also the most common
indication for retransplant.21 One of the clinical challenges
is deciding on the optimal timing for listing for retransplant,
however, as children with CAV are often completely
symptom free until they have a sudden death event.
Because of their relative clinical stability, 92% of children
with CAV survived to transplant despite having very long
wait times.
Mechanical Circulatory Support
Recent experience with MCS as bridge to transplant,
showed that patients receiving ECMO had a higher risk of
death while waiting but also had a shorter time to transplant
than other patient groups.22 When ECMO and VAD
groups were combined in this analysis, there was a higher
probability of heart transplant and also a higher probability
of being delisted because of clinical deterioration. Although
this appears contradictory, these higher status patients are
more likely to have an organ allocated sooner but also
have a higher chance of a devastating event rendering
them no longer a transplant candidate. With the increasing
use of pediatric VADs, there is a growing body of
experience, potentially impacting transplant wait times
and listing algorithms. A recent review of our institutional
experience with MCS as a bridge to transplant revealed a
28% waiting list mortality for patients receiving ECMO
compared with 13% for those receiving VAD support,
suggesting that not all forms of mechanical support should
be treated the same.22
Limitations of this study include (1) the single-center,
retrospective nature of the data; (2) the study period
spanning 18 years, introducing a possible era effect,
especially with regard to evolving management strate-
gies for patients with end-stage heart disease including
MCS; and (3) the proportion of patients with HLHS, a
population that is known to have significant preopera-
tive and postoperative morbidity and mortality. The
impact of changes in listing status for patients during
the waiting list period, from the time of initial listing
to status at transplant, could not be determined by this
study.The Journal of Thoracic and CaCONCLUSIONS
Risk factors for dying while waiting for a heart transplant
or being delisted because of clinical deterioration as a child
in Canada include age younger than 1 month, a diagnosis of
complex CHD, blood group O, and the use of MCS.
Knowledge of these risk factors can potentially influence
the timing of consideration of listing for transplant, guide
decisions during the wait for a donor organ to become
available, and help to change and improve organ allocation
algorithms to maximize donor organ availability for future
pediatric heart transplant recipients.References
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